SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (7531)12/17/2002 9:16:04 PM
From: Biomaven  Respond to of 52153
 
Tom,

I'm not sure it's going to have a dramatic effect on short-term prices. Remember IDPH will be hurt by Bexxar, and the MEDI partial win will certainly disappoint some as well.

But the turnaround by the FDA on Bexxar will certainly help the sector in the longer term. The FDA narrowly avoided egg on their faces by restoring Bexxar to active status just ahead of the meeting.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News